IL6 and COVID-19: Herein, as a proof-of-concept, we tested whether the modulation of the inflammatory response via IL-6 (colchicine), IL-17 (ixekizumab), and low doses of IL-2 could improve clinical outcomes of moderate to critical COVID-19 in hospitalized patients.